Oral treatments with the compounds significantly suppressed TNBS-induced expressions of IL-10, in addition to TNF-α, IL-6, and IL-1β in colon tissues, indicating that an anti-colitis activity of the compounds led to the resolution phase of TNBS-induced inflammation. The gene discussed is IL1B; the disease is colitis.